Search

Your search keyword '"Rodriguez, M. Alma"' showing total 9 results
Start Over Author "Rodriguez, M. Alma" Journal british journal of haematology
9 results on '"Rodriguez, M. Alma"'

2. The survival outcome of patients with relapsed/refractory peripheral T‐cell lymphoma‐not otherwise specified and angioimmunoblastic T‐cell lymphoma

Author

Chihara, Dai, Fanale, Michelle A., Miranda, Roberto N., Noorani, Mansoor, Westin, Jason R., Nastoupil, Loretta J., Hagemeister, Fredrick B., Fayad, Luis E., Romaguera, Jorge E., Samaniego, Felipe, Turturro, Francesco, Lee, Hun J., Neelapu, Sattva S., Rodriguez, M. Alma, Wang, Michael, Fowler, Nathan H., Davis, Richard E., Medeiros, L. Jeffrey, Hosing, Chitra, Nieto, Yago L., and Oki, Yasuhiro

Published
2017
Full Text
View/download PDF

3. Long‐term overall‐ and progression‐free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non‐Hodgkin lymphoma

Author

Khashab, Tamer, primary, Hagemeister, Fredrick, additional, Romaguera, Jorge E., additional, Fanale, Michelle A., additional, Pro, Barbara, additional, McLaughlin, Peter, additional, Rodriguez, M. Alma, additional, Neelapu, Sattva S., additional, Fayad, Luis, additional, Younes, Anas, additional, Feng, Lei, additional, Vega, Francisco, additional, Kwak, Larry W., additional, and Samaniego, Felipe, additional

Published
2019
Full Text
View/download PDF

5. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma

Author

Chihara, Dai, primary, Fanale, Michelle A., additional, Miranda, Roberto N., additional, Noorani, Mansoor, additional, Westin, Jason R., additional, Nastoupil, Loretta J., additional, Hagemeister, Fredrick B., additional, Fayad, Luis E., additional, Romaguera, Jorge E., additional, Samaniego, Felipe, additional, Turturro, Francesco, additional, Lee, Hun J., additional, Neelapu, Sattva S., additional, Rodriguez, M. Alma, additional, Wang, Michael, additional, Fowler, Nathan H., additional, Davis, Richard E., additional, Medeiros, L. Jeffrey, additional, Hosing, Chitra, additional, Nieto, Yago L., additional, and Oki, Yasuhiro, additional

Published
2016
Full Text
View/download PDF

6. Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma

Author

Chihara, Dai, primary, Westin, Jason R., additional, Miranda, Roberto N., additional, Cheah, Chan Y., additional, Oki, Yasuhiro, additional, Turturro, Francesco, additional, Romaguera, Jorge E., additional, Neelapu, Sattva S., additional, Nastoupil, Lorreta J., additional, Fayad, Luis E., additional, Rodriguez, M. Alma, additional, Fowler, Nathan H., additional, Orlowski, Robert Z., additional, Wang, Michael, additional, Hagemeister, Fredrick B., additional, Medeiros, L. Jeffrey, additional, and Fanale, Michelle A., additional

Published
2016
Full Text
View/download PDF

7. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma

Author

Chihara, Dai, primary, Pro, Barbara, additional, Loghavi, Sanam, additional, Miranda, Roberto N., additional, Medeiros, L. Jeffrey, additional, Fanale, Michelle A., additional, Hagemeister, Fredrick B., additional, Fayad, Luis E., additional, Romaguera, Jorge E., additional, Samaniego, Felipe, additional, Neelapu, Sattva S., additional, Younes, Anas, additional, Fowler, Nathan H., additional, Rodriguez, M. Alma, additional, Wang, Michael, additional, Kwak, Larry W., additional, McLaughlin, Peter, additional, Dang, Nam H., additional, and Oki, Yasuhiro, additional

Published
2015
Full Text
View/download PDF

8. Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas

Author

Samaniego, Felipe, primary, Hagemeister, Fredrick, additional, Romaguera, Jorge E., additional, Fanale, Michelle A., additional, Pro, Barbara, additional, McLaughlin, Peter, additional, Rodriguez, M. Alma, additional, Neelapu, Sattva S., additional, Fayad, Luis, additional, Younes, Anas, additional, Feng, Lei, additional, Berkova, Zuzana, additional, Khashab, Tamer, additional, Sehgal, Lalit, additional, Vega-Vasquez, Francisco, additional, and Kwak, Larry W., additional

Published
2015
Full Text
View/download PDF

9. Phase II study of HCVIDD/ MA in patients with newly diagnosed peripheral T-cell lymphoma.

Author

Chihara, Dai, Pro, Barbara, Loghavi, Sanam, Miranda, Roberto N., Medeiros, L. Jeffrey, Fanale, Michelle A., Hagemeister, Fredrick B., Fayad, Luis E., Romaguera, Jorge E., Samaniego, Felipe, Neelapu, Sattva S., Younes, Anas, Fowler, Nathan H., Rodriguez, M. Alma, Wang, Michael, Kwak, Larry W., McLaughlin, Peter, Dang, Nam H., and Oki, Yasuhiro

Subjects
LYMPHOMAS, T cells, HEMATOLOGIC malignancies, LYMPHOCYTES, PATIENTS
Abstract

A phase II study was performed to evaluate the efficacy of hyper-fractionated cyclophosphamide, vincristine, pegylated liposomal doxorubicin and dexamethasone alternating with methotrexate/cytarabine ( HCVIDD/ MA) in patients with newly diagnosed peripheral T-cell lymphoma ( PTCL), excluding ALK-positive anaplastic large cell lymphoma. Fifty-three patients were enrolled. Treatment was planned for up to 8 cycles but only 9% of patients received more than 6 cycles due primarily to disease progression ( n = 13) or prolonged thrombocytopenia ( n = 12). The overall response rate was 66% with a complete response rate of 57%. Median progression-free survival ( PFS) was 7·5 months. With a median follow-up of 7·6 years, 5-year PFS and overall survival ( OS) were 21% and 48%, respectively. The patients with extranodal Natural Killer-cell lymphoma had a shorter PFS (median, 2·4 months) than other subtypes. Grade 3/4 anaemia, neutropenia and thrombocytopenia were observed in 66%, 74% and 79% of patients, respectively. Of note, 23% of patients discontinued therapy due to prolonged thrombocytopenia. In conclusion, HCVIDD/ MA for the first-line treatment of PTCL patients is associated with significant myelosuppression leading to poor treatment adherence, and the response and survival outcomes with this regimen are similar to standard CHOP. This study was registered at as # NCT00290433. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results